Events & Presentations
Events & Presentations
April 16, 2024
AAN
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase 3 Study in Subjects with Relapsing Forms of Multiple Sclerosis
Read more February 29, 2024
ACTRIMS 2024
Patient Reported Outcomes, Safety and Tolerability in the Open Label Period of GA Depot, Phase 3, Multinational, Double-Blind, Placebo-Controlled Study in Patients with Relapsing Forms of Multiple Sclerosis
Read more October 11, 2023
ECTRIMS 2023
GA Depot (long-acting IM injection of glatiramer acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-Blind, Placebo-Controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis
Read more April 24, 2023
AAN 2023
Results of a Phase III, Multinational, Double Blind, Placebo-Controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks
Read more February 23, 2023
ACTRIMS 2023
Results of a Phase III, Multinational, Double Blind, Placebo-Controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks
Read more October 19, 2022
Webinar
Mapi Pharma to Host a Key Opinion Leader Webinar on Glatiramer Acetate Depot
Read more June 1, 2022
CMSC 2022
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy 1 Year Interim snapshot analysis
Read more April 3, 2022
AAN 2022
Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot
Read more April 4, 2022
AAN 2022
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot
Read more August 3, 2020
CMSC
Glatiramer Acetate (GA) Produced by Mapi Pharma is Equivalent to Commercially Available GA Preparations
Read more April 25, 2020
AAN 2020
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with relapsing remitting Multiple Sclerosis: safety, tolerability and efficacy (No Evidence of Disease Activity) subpopulation four-years analysis
Read more April 25, 2020
AAN 2020
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with primary progressive Multiple Sclerosis: safety and efficacy snapshot
Read more September 13, 2019
ECTRIMS 2019
Glatiramer acetate depot (extended-release) accumulated safety data in relapsing remitting multiple sclerosis & primary progressive multiple sclerosis phase IIa studies
Read more September 13, 2019
ECTRIMS 2019
Glatiramer acetate depot (extended-release) Phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (no evidence of disease activity) subpopulation three-years analysis
Read more May 30, 2019
CMSC 2019
Measurement of Anti-Glatiramer Acetate (GA) Antibodies in the Serum of RRMS Subjects Treated with GA Depot for 24 Months
Read more May 7, 2019
AAN 2019
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis
Read more October 12, 2018
ECTRIMS 2018
Glatiramer Acetate Depot (Extended-Release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (no evidence of disease activity) two-year analysis
Read more April 27, 2018
AAN 2018
Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis
Read more February 13, 2018
New York
KOL Webcast: Dr. Carlo Tornatore
Carlo Tornatore, MD, is Professor and Chairman of Neurology at Georgetown University Medical Center as well as Director of the Multiple Sclerosis Patient Centered Specialty Practice at Medstar Georgetown University Hospital in Washington, DC. Read more October 27, 2017
ECTRIMS 2017
Glatiramer acetate depot (extended-release) phase IIa one-year study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (no evidence of disease activity) analysis
Read more October 27, 2017
ECTRIMS 2017
Glatiramer Acetate Depot (extended-release) Phase IIA study in patients with Relapsing Remitting Multiple Sclerosis: Six months’ interim analysis
Read more April 20, 2016
AAN 2016
Pre-Clinical Studies and Evaluation of Treatment Need of Glatiramer Acetate Depot (Long Acting Injection)
Read more October 8, 2015
ECTRIMS 2015
Pre-clinical studies and evaluation of treatment need of glatiramer acetate depot
Read more June 11-14, 2015
ISNI 2015